News on Wellness

Vaccine Against Meningitis B Backed By JCVI In UK


A vaccine against meningitis protection is ready to be introduced in United kingdom. The government has been suggested for its approval by the Joint Committee on Vaccination and Immunisation (JCVI). It said in 2013 the jab was not cost-effective.

More than 1,800 people contract meningitis B each year in the UK and ten percent of those dies due to it. The most at risk are babies under one year and usually the cases peak at the age of 5 or 6 months.
The meningitis B contraction leads to inflammations of spinal cord and brain. It may damage the brain for entire life or may also lead to limb loss to one in four cases.

JCVI said the new vaccine should be rolled out as it is effective in preventing from meningitis B but the drug makers should make the price of it cost effective.

Also, the JCVI recommended to the government to add jab to the existing immunization schedule that begins at the age of just 2 months.

After the final approval of the vaccine around 700,000 babies will be eligible for it each year.

The vaccine, dubbed as Bexsero jab, is developed by Novartis. It is believed to be the only protection against meningitis B and tests shows it is effective against 73 percent of different strains of the disease.

Jab was licensed by the government last year in January for the use in Europe.

Leave a Reply

Your email address will not be published. Required fields are marked *